Comolli Giuditta, Torchio Martina, Lenta Elisa, Franceschetti Benvenuto, Chiesa Antonella, Calarota Sandra A, Baldanti Fausto, Scudeller Luigia, Marone Piero, Danova Marco
Laboratori di Ricerca Biotecnologie e S.C. Microbiologia e Virologia, Fondazione IRCCS San Matteo, Pavia, Italy.
Medicina Interna e Oncologia Medica, Ospedale di Vigevano, A.o. di Pavia, Italy.
New Microbiol. 2015 Jul;38(3):427-30. Epub 2015 Jul 6.
Infection and sepsis are major health problems in cancer patients. There is a need for the identification and validation of biomarkers to improve their early diagnosis and treatment. Emerging evidence showed that neutrophil CD64 is a highly sensitive and specific marker for systemic infection and sepsis in critically ill patients with various diseases but data on patients bearing solid tumors are still lacking. Using a dedicated flow cytometric assay we evaluated neutrophil CD64 expression in patients with advanced cancer without active infections to verify if it could be utilized as a reliable biomarker of early infections also in oncologic patients.
感染和脓毒症是癌症患者的主要健康问题。需要识别和验证生物标志物以改善其早期诊断和治疗。新出现的证据表明，中性粒细胞CD64是患有各种疾病的危重症患者全身性感染和脓毒症的高度敏感和特异的标志物，但实体瘤患者的数据仍然缺乏。我们使用专门的流式细胞术检测方法，评估了无活动性感染的晚期癌症患者中性粒细胞CD64的表达，以验证其是否也可作为肿瘤患者早期感染的可靠生物标志物。
